Abstract
Objective: To summarize the latest evidence on head and neck cancer epidemiology from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Subjects and Methods: INHANCE was established in 2004 to elucidate the etiology of head and neck cancer through pooled analyses of individual-level data on a large scale. We summarize results from recent INHANCE-based publications updating our 2015 overview. Results: Seventeen papers were published between 2015 and May 2020. These studies further define the nature of risks associated with tobacco and alcohol, and occupational exposures on head and neck cancer. The beneficial effects on incidence of head and neck cancer were identified for good oral health, endogenous and exogenous hormonal factors, and selected aspects of diet related to fruit and vegetables. INHANCE has begun to develop risk prediction models and to pool follow-up data on their studies, finding that ~30% of cases had cancer recurrence and 9% second primary cancers, with overall- and disease-specific 5-year-survival of 51% and 57%, respectively. Conclusions: The number and importance of INHANCE scientific findings provides further evidence of the advantages of large-scale internationally collaborative projects and will support the development of prevention strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 73-93 |
Number of pages | 21 |
Journal | Oral Diseases |
Volume | 27 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
All Science Journal Classification (ASJC) codes
- Otorhinolaryngology
- Dentistry(all)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Lessons learned from the INHANCE consortium : An overview of recent results on head and neck cancer. / the INHANCE Consortium investigators.
In: Oral Diseases, Vol. 27, No. 1, 01.2021, p. 73-93.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Lessons learned from the INHANCE consortium
T2 - An overview of recent results on head and neck cancer
AU - the INHANCE Consortium investigators
AU - Bravi, Francesca
AU - Lee, Yuan Chin Amy
AU - Hashibe, Mia
AU - Boffetta, Paolo
AU - Conway, David I.
AU - Ferraroni, Monica
AU - La Vecchia, Carlo
AU - Edefonti, Valeria
AU - Agudo, Antonio
AU - Ahrens, Wolfgang
AU - Benhamou, Simone
AU - Boccia, Stefania
AU - Brennan, Paul
AU - Brenner, Hermann
AU - Cadoni, Gabriella
AU - Canova, Cristina
AU - Chen, Chu
AU - Chuang, Shu Chun
AU - Curado, Maria Paula
AU - Dal Maso, Luigino
AU - Daudt, Alexander W.
AU - D'Souza, Gypsyamber
AU - Fabianova, Eleonora
AU - Fernandez, Leticia
AU - Franceschi, Silvia
AU - Garavello, Werner
AU - Gillison, Maura
AU - Gross, Neil D.
AU - Hayes, Richard B.
AU - Healy, Claire
AU - Herrero, Rolando
AU - Holcatova, Ivana
AU - Kelsey, Karl
AU - Kjaerheim, Kristina
AU - Koifman, Rosalina
AU - Lagiou, Pagona
AU - Lazarus, Philip
AU - Levi, Fabio
AU - Li, Guojun
AU - Lissowska, Jolanta
AU - Luce, Daniele
AU - Macfarlane, Gary J.
AU - Mates, Dana
AU - Matsuo, Keitaro
AU - McClean, Michael
AU - Menezes, Ana
AU - Menvielle, Gwenn
AU - Morgenstern, Hal
AU - Moyses, Raquel A.
AU - Muscat, Joshua
N1 - Funding Information: The authors would like to thank Xavier Castellsagué who collected data in the IARC International Multicenter study and passed away in 2016. The INHANCE consortium and the single studies included were supported by grants from the: National Institutes of Health (NIH) [no grant number provided for the INHANCE Pooled Data Project and Intramural Research Program for the Puerto Rico study, grant numbers P01CA068384, K07CA104231 for the New York Multicenter study, grant numbers R01CA048996, R01DE012609 for the Seattle (1985‐1995) study, grant number TW001500 for the Fogarty International Research Collaboration Award (FIRCA) supporting the Iowa study, grant number R01CA061188 for the North Carolina (1994‐1997) study, grant numbers P01CA068384, K07CA104231, R01DE013158 for the Tampa study, grant numbers P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667 for the Los Angeles study, grant numbers R01CA078609, R01CA100679 for the Boston study, grant number R01CA051845 for the MSKCC study, grant number R01CA030022 for the Seattle‐Leo study, grant number DE016631 and the Intramural Research Program for the Baltimore study]; National Cancer Institute (NCI) at the National Institutes of Health (NIH) [grant number R03CA113157 for the INHANCE Pooled Data Project, no grant number provided for the Intramural Research Program supporting the Puerto Rico study and the US Multicenter study, grant number R01‐CA90731 and the Intramural Research Program for the North Carolina (2002‐2006) study]; National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH) [grant number R03DE016611 for the INHANCE Pooled Data Project, grant numbers R01DE011979, R01DE013110 for the Iowa study, no grant number provided for the Intramural Research Program supporting the Puerto Rico study]; Italian Association for Research on Cancer (AIRC) [no grant number provided for the Milan (1984‐1989) study, for the Aviano study, for the Italy Multicenter study, and for the Rome study, grant number 10068 for the Milan (2006‐2009) study]; Italian League against Cancer [no grant number provided for the Aviano and Italy Multicenter studies]; Italian Ministry of Research [no grant number provided for the Aviano and Italy Multicenter studies]; The Swiss Research against cancer/Oncosuisse [grant numbers KFS‐700, OCS‐1633 for the Switzerland study, grant number KFS1096‐09‐2000 for the France (1987‐1992) study]; European Commission [grant number IC18‐CT97‐0222 (INCO‐DC Program) for the Latin America study, INCO‐COPERNICUS Program Contract number IC15‐ CT98‐0332 for the Central Europe study]; Veterans Affairs Merit Review Funds [no grant number provided for the Iowa study]; National Institute of Environmental Health Sciences (NIEHS) [grant number P30ES010126 for the North Carolina (1994‐1997) study, grant number P30ES010126 for the North Carolina (2002‐2006) study]; Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center [no grant number provided for the Los Angeles study]; Fondo para la Investigacion Cientifica y Tecnologica Argentina (FONCYT) [no grant number provided for the Latin America study]; Institut Hospital del Mar d’Investigacions Mediquès (IMIM) [no grant number provided for the Latin America study]; Fundação de Amparo à Pesquisa no Estado de São Paulo (FAPESP) [grant number 01/01768‐2 for the Latin America study, grant numbers GENCAPO 04/12054‐9, 10/51168‐0 for the Sao Paulo study]; Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government [grant number FIS 97/0024, FIS 97/0662, BAE 01/5013 for the International Multicenter study]; International Union Against Cancer (UICC) [no grant number provided for the International Multicenter study]; Yamagiwa‐Yoshida Memorial International Cancer Study Grant [no grant number provided for the International Multicenter study]; European Community (5th Framework Programme) [grant number QLK1‐CT‐2001‐00182 for the Western Europe study]; Scientific Research grant from the Ministry of Education, Science, Sports, Culture and Technology of Japan [grant number 17015052 for the Japan (1988‐2000) study and Japan (2001‐2005) study]; Third‐Term Comprehensive 10‐Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan [grant number H20‐002 for the Japan (1988‐2000) study and Japan (2001‐2005) study]; Italian Foundation for Cancer Research (FIRC) [no grant number provided for the Milan (2006‐2009) study]; Italian Ministry of Education—PRIN 2009 Program [grant number X8YCBN for the Milan study (2006‐2009) study]; Fribourg League against Cancer [grant number FOR381.88 for the France (1987‐1992) study]; Swiss Cancer Research [grant number AKT 617 for the France (1987‐1992) study]; Gustave‐Roussy Institute [grant number 88D28 for the France (1987‐1992) study]; French National Research Agency (ANR) [no grant number provided for the France Multicenter (2001‐2007) study]; French National Cancer Institute (INCA) [no grant number provided for the France Multicenter (2001‐2007) study]; French Agency for Food, Environmental and Occupational Health and Safety (ANSES) [no grant number provided for the France Multicenter (2001‐2007) study]; French Institute for Public Health Surveillance (InVS) [no grant number provided for the France Multicenter (2001‐2007) study]; Fondation pour la Recherche Médicale (FRM) [no grant number provided for the France Multicenter (2001‐2007) study]; Fondation de France [no grant number provided for the France Multicenter (2001‐2007) study]; Fondation ARC pour la Recherche sur le Cancer [no grant number provided for the France Multicenter (2001‐2007) study]; French Ministry of Labour (Direction Générale du Travail) [no grant number provided for the France Multicenter (2001‐2007) study]; French Ministry of Health (Direction Générale de la Santé) [no grant number provided for the France Multicenter (2001‐2007) study]; World Cancer Research Fund [no grant number provided for the Central Europe study]; Ministry of Science, Research and Arts Baden‐Wurttemberg [no grant number provided for the Germany‐Saarland study]; German Ministry of Education and Research [grant number 01GB9702/3 for the Germany‐Heidelberg study]; Johns Hopkins Richard Gelb Cancer Prevention Award [no grant number for the HOTSPOT study]; no grants provided for the France (1989 – 1991), Houston, and Buffalo studies; VE was supported by Università degli Studi di Milano “Young Investigator Grant Program 2017.” Publisher Copyright: © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved
PY - 2021/1
Y1 - 2021/1
N2 - Objective: To summarize the latest evidence on head and neck cancer epidemiology from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Subjects and Methods: INHANCE was established in 2004 to elucidate the etiology of head and neck cancer through pooled analyses of individual-level data on a large scale. We summarize results from recent INHANCE-based publications updating our 2015 overview. Results: Seventeen papers were published between 2015 and May 2020. These studies further define the nature of risks associated with tobacco and alcohol, and occupational exposures on head and neck cancer. The beneficial effects on incidence of head and neck cancer were identified for good oral health, endogenous and exogenous hormonal factors, and selected aspects of diet related to fruit and vegetables. INHANCE has begun to develop risk prediction models and to pool follow-up data on their studies, finding that ~30% of cases had cancer recurrence and 9% second primary cancers, with overall- and disease-specific 5-year-survival of 51% and 57%, respectively. Conclusions: The number and importance of INHANCE scientific findings provides further evidence of the advantages of large-scale internationally collaborative projects and will support the development of prevention strategies.
AB - Objective: To summarize the latest evidence on head and neck cancer epidemiology from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Subjects and Methods: INHANCE was established in 2004 to elucidate the etiology of head and neck cancer through pooled analyses of individual-level data on a large scale. We summarize results from recent INHANCE-based publications updating our 2015 overview. Results: Seventeen papers were published between 2015 and May 2020. These studies further define the nature of risks associated with tobacco and alcohol, and occupational exposures on head and neck cancer. The beneficial effects on incidence of head and neck cancer were identified for good oral health, endogenous and exogenous hormonal factors, and selected aspects of diet related to fruit and vegetables. INHANCE has begun to develop risk prediction models and to pool follow-up data on their studies, finding that ~30% of cases had cancer recurrence and 9% second primary cancers, with overall- and disease-specific 5-year-survival of 51% and 57%, respectively. Conclusions: The number and importance of INHANCE scientific findings provides further evidence of the advantages of large-scale internationally collaborative projects and will support the development of prevention strategies.
UR - http://www.scopus.com/inward/record.url?scp=85088014022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088014022&partnerID=8YFLogxK
U2 - 10.1111/odi.13502
DO - 10.1111/odi.13502
M3 - Review article
C2 - 32569410
AN - SCOPUS:85088014022
VL - 27
SP - 73
EP - 93
JO - Oral Diseases
JF - Oral Diseases
SN - 1354-523X
IS - 1
ER -